Clinical Trial

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated April 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-05.
Trial Details
NCT Number NCT06970145
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Craniopharyngiomas
Enrollment 57 participants
Start Date 2025-04-25
Primary Completion 2026-04-20 (estimated)
Study Completion 2028-04-20 (estimated)
Updated on ClinicalTrials.gov 2025-11-18